



WEDNESDAY, 14th February 2018 COMMENCING 09:30 AM
AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|--------------------------------|--------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0218 |

To protect commercial confidentiality the following appraisal will be held in private

- | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 5. Appraisal 1: Full Submission (WPAS) Rolapitant (Varuby®) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. | 2/AWMSG/0218 Appendices |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|

The meeting will now open to the public

- | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 6. Chairman's report (verbal update) | |
| 7. AWMSG Five Year Strategy 2018-2023 | 3/AWMSG/0218 |
| 8. National Prescribing Indicators 2017-2018 Data to September 2017 | 4/AWMSG/0218 |
| 9. National Prescribing Indicators 2018-2019 | 5/AWMSG/0218 |
| 10. National Prescribing Indicators 2018-2019 – Supporting Information | 5a/AWMSG/0218 |
| 11. Feedback from All Wales Prescribing Advisory Group meeting held on 13th December 2017 | 6/AWMSG/0218 |
| 12. Appraisal 2: Limited Submission Lopinavir/ritonavir (Kaletra®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus) infected children aged from 14 days to less than 2 years old | 7/AWMSG/0218 Appendices |

- | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 13. | Appraisal 3: Limited Submission Lacosamide (Vimpat®) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years of age to less than 15 years of age with epilepsy | 8/AWMSG/0218 Appendices |
| 14. | Appraisal 4: Limited Submission Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). | 9/AWMSG/0218 Appendices |
| 15. | All Wales Guide: Pharmacotherapy for Smoking Cessation | 10/AWMSG/0218 |
| 16. | Safe Use of Proton Pump Inhibitors | 11/AWMSG/0218 |
| 17 | Common Ailments Service Formulary | 12/AWMSG/0218 |

Date of next meeting – Wednesday, 14th March 2018 in Cardiff